Thomas F. Bumol

3.8k total citations · 1 hit paper
43 papers, 2.8k citations indexed

About

Thomas F. Bumol is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Thomas F. Bumol has authored 43 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 17 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Oncology. Recurrent topics in Thomas F. Bumol's work include Monoclonal and Polyclonal Antibodies Research (17 papers), Glycosylation and Glycoproteins Research (11 papers) and HER2/EGFR in Cancer Research (7 papers). Thomas F. Bumol is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), Glycosylation and Glycoproteins Research (11 papers) and HER2/EGFR in Cancer Research (7 papers). Thomas F. Bumol collaborates with scholars based in United States, Germany and Canada. Thomas F. Bumol's co-authors include R. Reisfeld, Alexei Kharitonenkov, David E. Moller, Gregory Gaich, Haoda Fu, Jenny Y. Chien, William L. Holland, Leonard C. Glass, Mark A. Deeg and L D Apelgren and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Biological Chemistry.

In The Last Decade

Thomas F. Bumol

42 papers receiving 2.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

2013 730 citations Gregory Gaich, Jenny Y. Chien et al. Cell Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas F. Bumol United States	24	1.7k	692	603	482	266	43	2.8k
Siegfried Stengelin Germany	21	1.3k 0.8×	680 1.0×	377 0.6×	813 1.7×	164 0.6×	33	3.0k
Desiree Ehleiter United States	15	2.2k 1.3×	609 0.9×	775 1.3×	383 0.8×	409 1.5×	18	3.6k
Paola Capodieci United States	19	2.2k 1.3×	1.2k 1.8×	537 0.9×	343 0.7×	137 0.5×	31	3.7k
Sergei M. Danilov United States	36	1.7k 1.0×	391 0.6×	603 1.0×	313 0.6×	410 1.5×	123	3.7k
Connie L. Finstad United States	29	927 0.5×	856 1.2×	463 0.8×	527 1.1×	224 0.8×	51	2.3k
Cecil R. Stockard United States	28	1.0k 0.6×	490 0.7×	278 0.5×	441 0.9×	175 0.7×	64	2.4k
Peter B. Alexander United States	23	1.3k 0.8×	721 1.0×	217 0.4×	421 0.9×	205 0.8×	41	2.5k
Susan W. Sunnarborg United States	18	1.4k 0.8×	1.1k 1.6×	316 0.5×	500 1.0×	179 0.7×	23	3.1k
R.R. Weichselbaum United States	28	1.8k 1.0×	1.2k 1.7×	724 1.2×	465 1.0×	114 0.4×	64	3.5k
Louis Fabri Australia	26	1.4k 0.8×	1.1k 1.5×	319 0.5×	771 1.6×	89 0.3×	55	2.6k

Countries citing papers authored by Thomas F. Bumol

Since Specialization

Citations

This map shows the geographic impact of Thomas F. Bumol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas F. Bumol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas F. Bumol more than expected).

Fields of papers citing papers by Thomas F. Bumol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas F. Bumol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas F. Bumol. The network helps show where Thomas F. Bumol may publish in the future.

Co-authorship network of co-authors of Thomas F. Bumol

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas F. Bumol. A scholar is included among the top collaborators of Thomas F. Bumol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas F. Bumol. Thomas F. Bumol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shasha, Carolyn, David R. Glass, Laura Islas, et al.. (2025). Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy. Blood. 145(26). 3113–3123. 2 indexed citations

Okada, Lauren, Morgan Weiss, Julian Reading, et al.. (2024). MOCHA’s advanced statistical modeling of scATAC-seq data enables functional genomic inference in large human cohorts. Nature Communications. 15(1). 2 indexed citations

Talla, Aarthi, Suhas Vasaikar, Gregory L. Szeto, et al.. (2023). Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nature Communications. 14(1). 3417–3417. 70 indexed citations

Vasaikar, Suhas, Adam K. Savage, Elliott Swanson, et al.. (2023). A comprehensive platform for analyzing longitudinal multi-omics data. Nature Communications. 14(1). 1684–1684. 21 indexed citations

Genge, Palak C., Alexander T. Heubeck, Elliott Swanson, et al.. (2021). Optimized workflow for human PBMC multiomic immunosurveillance studies. STAR Protocols. 2(4). 100900–100900. 6 indexed citations

Gaich, Gregory, Jenny Y. Chien, Haoda Fu, et al.. (2013). The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes. Cell Metabolism. 18(3). 333–340. 730 indexed citations breakdown →

Lahn, Michael, Gabriele Köhler, Karen Sundell, et al.. (2004). Protein Kinase C Alpha Expression in Breast and Ovarian Cancer. Oncology. 67(1). 1–10. 77 indexed citations

Archer, Robert A., Joseph M. Pawlak, Lisa S. Beavers, et al.. (1995). Synthesis and Biological Evaluation of a New Series of Sterols as Potential Hypocholesterolemic Agents. Journal of Medicinal Chemistry. 38(2). 277–288. 22 indexed citations

Evans, Glenn F., William R. Bensch, L D Apelgren, et al.. (1994). Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: effects on HDL subspecies, quantity, and apolipoprotein distribution.. Journal of Lipid Research. 35(9). 1634–1645. 27 indexed citations

10.

Williams, J. Koudy, Dwight A. Bellinger, Timothy C. Nichols, et al.. (1993). Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a).. Arteriosclerosis and Thrombosis A Journal of Vascular Biology. 13(4). 548–554. 42 indexed citations

11.

Briggs, Steve, George J. Cullinan, David A. Johnson, et al.. (1989). New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. Journal of Medicinal Chemistry. 32(3). 548–555. 95 indexed citations

12.

Strnad, Joann, Lisa S. Beavers, L D Apelgren, et al.. (1989). Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA.. PubMed. 49(2). 314–7. 115 indexed citations

13.

Bumol, Thomas F., et al.. (1988). Characterization of the Human Tumor and Normal Tissue Reactivity of the KS1/4 Monoclonal Antibody. Hybridoma. 7(4). 407–415. 56 indexed citations

14.

Johnson, Irving S., et al.. (1987). Monoclonal antibody drug conjugates for site-directed cancer chemotherapy: preclinical pharmacology and toxicology studies. Cancer Treatment Reviews. 14(3-4). 193–196. 14 indexed citations

15.

Apelgren, L D, et al.. (1987). Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.. Journal of Pharmacology and Experimental Therapeutics. 241(2). 695–703. 20 indexed citations

16.

Reisfeld, R., John R. Harper, & Thomas F. Bumol. (1984). Human tumor-associated antigens defined by monoclonal antibodies.. PubMed. 5(1). 27–53. 8 indexed citations

17.

Harper, John R., Thomas F. Bumol, & Ralph A. Reisfeld. (1982). Serological and Biochemical Analyses of Monoclonal Antibodies to Human Melanoma-Associated Antigens. Hybridoma. 1(4). 423–432. 23 indexed citations

18.

Bumol, Thomas F., Darwin O. Chee, & R. Reisfeld. (1982). Immunochemical and Biosynthetic Analysis of Monoclonal Antibody-Defined Melanoma-Associated Antigen. Hybridoma. 1(3). 283–292. 13 indexed citations

19.

Bumol, Thomas F. & R. Reisfeld. (1982). Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells.. Proceedings of the National Academy of Sciences. 79(4). 1245–1249. 251 indexed citations

20.

Handwerger, Barry S., et al.. (1981). The mitogenic properties of rabbit anti-mouse brain serum. Cellular Immunology. 62(1). 60–73. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact